Retinset
Founded Year
2014About Retinset
Retinset develops novel classes of medicines to treat neurovascular ophthalmic pathologies. The company's leading program (BSL01) is an eyedrop formulation to treat Diabetic Retinopathy (DR) from a very early stage.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Retinset Patents
Retinset has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/22/2016 | 7/21/2020 | G protein coupled receptors, Diabetes, Fluoroarenes, Rare diseases, Diseases of the eye and adnexa | Grant |
Application Date | 3/22/2016 |
|---|---|
Grant Date | 7/21/2020 |
Title | |
Related Topics | G protein coupled receptors, Diabetes, Fluoroarenes, Rare diseases, Diseases of the eye and adnexa |
Status | Grant |
Retinset Frequently Asked Questions (FAQ)
When was Retinset founded?
Retinset was founded in 2014.
Where is Retinset's headquarters?
Retinset's headquarters is located at Carrer Amposta, 20, Barcelona.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
